• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis abstracts at 2017 European Respiratory Society Conference
Share
News, ProteaseTag®

ProAxsis abstracts at 2017 European Respiratory Society Conference

September 6, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes place between September 9th-13thin Milan, Italy. The company has had four abstracts accepted for presentation by the conference review committee, details of which are below:

Investigating optimal sputum processing methods for active neutrophil elastase quantification – SESSION 353 TECHNIQUES IN BIOMARKER SELECTION – Oral Presentation (presenting author Dr Charlene Robb) – MONDAY, SEPTEMBER 11, 2017 14:45—16:45h

The Development of a Novel Immunoassay for the Quantification of Active Tryptase – CHRONIC AIRWAY DISEASE: MARKERS OF DISEASE IMPACT – Thematic Poster Session (presenting author Dr Timothy Ferguson) – TUESDAY, SEPTEMBER 12, 2017 12:50-14:40h

Development of a Novel Immunoassay for the Measurement of Active Plasmin in Patients with IPF – CHRONIC AIRWAY DISEASE: MARKERS OF DISEASE IMPACT – Thematic Poster Session (presenting author Dr Darragh McCafferty) – TUESDAY, SEPTEMBER 12, 2017 12:50-14:40h

Examining the specificity of an internally quenched fluorogenic substrate for neutrophil elastase – CHRONIC AIRWAY DISEASE: MARKERS OF DISEASE IMPACT – Thematic Poster Session (presenting author Dr Charlene Robb) – TUESDAY, SEPTEMBER 12, 2017 12:50-14:40h

Dr David Ribeiro, CEO of ProAxsis, said: “ERS is an international organisation that brings together physicians, healthcare professionals, scientists and other experts working in respiratory medicine from all over the World. ProAxsis is very pleased to have such strong scientific presence at this key event, which gives us the opportunity to raise awareness of the multiple diagnostic offerings the company has in development.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

September 6, 2017
No comments yet

Related News

Other posts that you should not miss.
Announcements, News

ProAxsis appoints experienced Sales and Marketing Manager

April 20, 2016
-
Posted by Webmaster

ProAxsis is pleased to announce the appointment of Sarah Ganniclefft to the newly created role of Sales …

Read More
April 20, 2016
Posted by Webmaster
News

ProAxsis announces commercial team expansion

June 21, 2021
-
Posted by David Ribeiro

As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce …

Read More
June 21, 2021
Posted by David Ribeiro
Conferences, News

ProAxsis CEO to present at Biotrinity 2016

April 19, 2016
-
Posted by Webmaster

Dr David Ribeiro, CEO of ProAxsis, will be attending the 10th anniversary Biotrinity conference, taking place in London on …

Read More
April 19, 2016
Posted by Webmaster
← PREVIOUS POST
ProAxsis signs partnership with a large US based biotechnology company
NEXT POST →
ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis abstracts at 2017 European Respiratory Society Conference - ProAxsis